Phathom Pharmaceuticals, Inc. PHAT

Initiation of registrational Phase 3 study of VOQUEZNA® (vonoprazan) for as-needed (PRN) use in Non-Erosive Reflux Disease (NERD) builds on previously reported positive Phase 2 dataTopline results expected in the first quarter of 2028pHalcon-NERD-302, if successful, is intended to support a potential VOQUEZNA label expansion to include as-needed treatment of heartburn episodes in patients with Non-Erosive GERD, a treatment regimen of interest to patients for which proton pump inhibitors (PPIs) a

Leerink said that VOQUEZNA competes in a “highly genericized” gastroesophageal reflux disease market against long-available proton pump inhibitors (PPI).

The latest update on Phathom Pharmaceuticals centers on a reset in valuation anchors, with fair value moving from US$23.70 to US$21.50 as analysts revisit their price targets. This change reflects a more cautious tone in recent research, where Q2 results, revised 2026 revenue guidance, and fresh views on Voquezna's commercial path are all feeding into how targets are being set. As you read on, you will see what is driving the evolving narrative and how to keep track of the key signals. Stay...

Phathom lowered its full-year 2026 net revenue outlook to $310–325 million from the prior $320–345 million range.

Phathom Pharmaceuticals Inc (PHAT) achieves milestone profitability and strong revenue growth, but faces physician friction in the prior authorization process for Voquezna.

~1.7 million total VOQUEZNA® prescriptions filled to dateRecord Q2 2026 net revenues of $74.3 million, increased 88% vs. Q2 2025 and 27% vs. Q1 2026Q2 operating expenses of $63.1 million, reduced by 33% vs. Q2 2025Initiating Phase 3 clinical trial evaluating as-needed dosing of VOQUEZNA® in patients with Non-Erosive GERD (NERD)Updated full-year 2026 financial guidanceConference call and webcast today, July 30, 2026, at 8:00 a.m. EDT FLORHAM PARK, N.J., July 30, 2026 (GLOBE NEWSWIRE) -- Phathom P

Management to host conference call on Thursday, July 30, 2026, at 8:00 am EDTFLORHAM PARK, N.J., July 20, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, today announced that it will host a live webcast at 8:00 am EDT on Thursday, July 30, 2026, to report its second quarter 2026 financial results and provide a business update. A live webcast and additi

This trial is the first large, placebo-controlled clinical trial of an acid suppression treatment in EoETopline results for the double-blind 12-week treatment portion of the study are expected in Q4 of 2026 FLORHAM PARK, N.J., June 23, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced it has completed enrollment in its Phase 2 pHalcon-EoE

FLORHAM PARK, N.J., May 22, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following upcoming investor conferences in May and June: Craig-Hallum 23rd Annual Institutional Investor Conference in Minneapolis, MNDate: Thursday, May 28, 2026 Management to participate i

31 vonoprazan-related clinical abstracts presented at Digestive Disease Week (DDW) 2026, including 28 independent analyses across GI conditions and three Phathom-sponsored clinical research abstractsIndependent investigator-initiated studies reported findings on treatment of GERD, H. pylori eradication, long-term safety, and vonoprazan use post endoscopic submucosal dissection (ESD)Phathom-sponsored analysis of heartburn and regurgitation in patients on vonoprazan from the Phase 3 pHalcon-NERD-3

Phathom Pharmaceuticals, Inc. reported first-quarter 2026 results showing a net loss of US$30.37 million, down from US$94.32 million a year earlier, with basic loss per share from continuing operations narrowing to US$0.37 from US$1.31. The company also maintained its 2026 guidance, including expected net revenues of US$320 million to US$345 million and a target of reaching operating profitability, excluding stock-based compensation, by the third quarter and for the full year, while changing...

Price targets on Phathom Pharmaceuticals have been refreshed in recent reports, with some moving to US$25 and others to US$13 as analysts rework their models. These updated targets reflect a mix of optimism around the company’s stated goal of reaching profitability in early Q3 2026, along with caution around long term exclusivity, regulatory factors, and commercialization efforts. As you read on, you will see how to interpret these shifting targets and track the evolving Street narrative...

FLORHAM PARK, N.J., May 01, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, today announced its participation in the Digestive Disease Week® (DDW) 2026 annual meeting, being held May 2–5 in Chicago, Illinois. Phathom will engage with the medical and scientific community through a series of activities, including a product theater presentation on VOQUEZN

Phathom Pharmaceuticals (NASDAQ:PHAT) reported first-quarter 2026 net revenue of $58.3 million, more than doubling the $28.5 million recorded in the same period a year ago, as the company emphasized continued progress in deepening adoption of its acid-suppression medicine VOQUEZNA among gastroentero

Moby summary of Phathom Pharmaceuticals, Inc.'s Q1 2026 earnings call